MSB 0.66% $1.53 mesoblast limited

Cell Therapy News/Articles, page-13547

  1. 4,503 Posts.
    lightbulb Created with Sketch. 348
    MSB related, does sound familiar?:
    (Not a cross promote (demote), posted for information as stem cell related.)

    "Athersys tries to post-hoc-analyze its way out of another trial fail for stroke stem cell therapy...
    stem cell therapy has failed yet again. Then, as it’s done in the past, the company pivoted to a post-hoc analysis, picking out a subset of younger patients to show where their treatment had an effect. Even then, the results only approached but did not reach statistical significance." LINK

    At least FDA can't be blamed this time.

    Tread carefully mums/dads/newbies and DYOR.

    Just sayin'. rolleyes.png

    https://hotcopper.com.au/data/attachments/4362/4362374-8771861b4c9ed07cee6cac814754328a.jpg



 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.53
Change
0.010(0.66%)
Mkt cap ! $1.741B
Open High Low Value Volume
$1.50 $1.54 $1.48 $5.605M 3.713M

Buyers (Bids)

No. Vol. Price($)
5 55197 $1.53
 

Sellers (Offers)

Price($) Vol. No.
$1.53 29782 3
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.